INTRODUCTION
Autoimmune diseases are a series of disorders and conditions caused by immune intolerance to self-antigens which attack specific target organs and display diverse clinical signs 1, 2 . Over 100 classifications of autoimmune diseases have been documented, such as rheumatoid arthritis (RA) 3 and inflammatory bowel disease (IBD, including Ulcerative Colitis and
Crohn's Disease) 4 . Autoimmune diseases are chronic diseases with complicated pathology and diverse clinical signs, underlying which are alterations in cytokine expression and immune cell infiltration. Among the pro-inflammatory cytokines involved, tumor necrosis factor alpha (TNF-α) has received great attention due to its position at the apex of the proinflammatory cytokine cascade and its dominance in the pathogenesis of various disease processes 5, 6 , and in particular, autoimmune disorders 7, 8 . TNF-α inhibitors (TNFI), including etanercept (Enbrel), infliximab (Remicade), and adalimumab (Humira), have been accepted as effective anti-inflammatory therapies and are among the most successful biotech pharmaceuticals [9] [10] [11] . Although treatment with TNFI is highly effective in ameliorating disease in some patients, current TNFI fail to provide effective treatment for up to 50% of patients 12, 13 . In addition to high cost (upwards of $20,000 per year per patient using anti-TNF biologics), current TNFI have been found to increase cancer risk 14 and cause infection in some patients 15 . Thus identification and characterization of novel, safer, and more cost-effective antagonists of TNF-α, in particular with different inhibitory properties, are of great importance from both a pathophysiological and a therapeutic standpoint. Considering the fact that drug development is time consuming and extremely expensive, costing ~15 years in time and 800 million USD on average 16 , we adopted a strategic approach involving the repurposed use of clinically approved drugs. A drug library composed of FDA approved drugs was screened both in vitro and in vivo by use of TNF-α/NF-κB reporter constructs and mice, which led to the identification of Terfenadine and its active metabolite Fexofenadine as inhibitors of TNF-α signaling.
Terfenadine and Fexofenadine are two well-known histamine receptor 1 antagonists and used for treating allergic diseases 17 . Terfenadine, a first generation anti-histamine drug, has been clinically suspended due to potential adverse events. In contrast, Fexofenadine, the major active metabolite of Terfenadine and a non-sedative third generation antihistamine drug 18 ,
does not have proarrhythmic risk associated with use of Terfenadine, and is marketed as an over-the-counter (OTC) drug due to its safety. Fexofenadine has been being widely used to treat various allergic diseases, like allergic rhinitis, conjunctivitis and chronic idiopathic urticarial [17] [18] [19] [20] .
In our efforts to elucidate the molecular mechanisms underlying Fexofenadine-and
Terfenadine-mediated inhibition of TNF-α signaling, we identified cytosolic phospholipase A2 (cPLA2) as a novel target of these two drugs. The major function of cPLA2 is to promote phospholipid hydrolysis to produce arachidonic acid (AA) 21 ; AA activates NF-ĸB and is involved in the pathogeneses of various conditions 22 , including inflammatory and autoimmune diseases 23 .
Herein we present comprehensive evidences demonstrating that both Fexofenadine and
Terfenadine act as the inhibitors of TNF/NF-ĸB signaling and are therapeutic against autoimmune diseases. Additionally, we also provide evidences revealing that these two drugs bound to cPLA2 and inhibited its enzymatic activity, which is required for their inhibition of TNF-α signaling.
RESULTS

Fexofenadine and Terfenadine act as the antagonists of TNF-α and inhibit TNF-α signaling and activity
To isolate the small molecule drugs that inhibit canonical TNF-α/NF-κB signaling pathway, a drug library containing 1046 FDA-approved drugs was initially screened using NF-κB-bla THP-1 cell line in which NF-κB beta-lactamase reporter gene was stably integrated. After repeating three times, twenty-four drugs that potently inhibited TNF-α/NF-κB activation of beta-lactamase were identified ( Fig. S1a-b) . These twenty-four isolates were subjected to a second round screen using RAW 264.7 macrophages transiently transfected with an NF-κB luciferase reporter gene. Under such conditions, only the most potent anti-TNF-α/NF-κB signaling drugs are positively screened. Eight drugs among the twenty-four candidates originally isolated were selected ( Fig. S2a-b) . In order to identify the drugs that retain anti-TNF-α/NF-κB activity in vivo, we performed a third round screen with NF-κB-Luc reporter mice. We first crossed TNF transgenic (TNF-tg) to NF-κB-Luc reporter mice to generate TNF-tg:NF-κB-Luc double mutant mice. Overexpression of TNF-α effectively activated NF-κB luciferase in vivo. IVIS was implemented for whole animal bioluminescence imaging following intraperitoneal injection of eight selected drugs into TNF-tg:NF-κB-Luc double mutant mice. Five drugs, including Terfenadine and its active metabolite Fexofenadine, were shown to effectively inhibit TNF-tg:NF-κB activated luciferase in vivo (Fig. S3) . Among these five identified drugs, three, including one anti-cancer drug, are known to have severe side-effects and are not suitable for treating chronic inflammatory diseases, such as rheumatoid arthritis, we accordingly selected Fexofenadine and Terfenadine for further analyses (Fig. 1a) .
We first examined the inhibition of Fexofenadine and Terfenadine on TNF-activated NF-κB pathway and downstream genes through RNA-seq with bone-marrow-derived macrophages (BMDMs) (Fig. 1b-c, Fig. S4 ). Nearly all TNF-α induced genes, especially genes encoding inflammatory cytokines, such as IL-1β, IL-6, were clearly down-regulated by Fexofenadine and Terfenadine. The lists of TNF-α inducible genes that were inhibited by Fexofenadine were used for transcription factor enrichment analysis with TFactS 24 , which led to the isolation of NF-κB1 p105 and RelA p65 as significantly regulated transcription factors by Fexofenadine (Fig. 1c) .
In order to further validate the anti-TNF-α activity of Fexofenadine and Terfenadine, we next selected a couple of well-known TNF-α downstream inflammatory mediators for further assays. Quantitative real time PCR revealed that both Fexofenadine and Terfenadine dose-dependently inhibited TNF-α induced mRNA expressions of IL-1β, IL-6 and Nos-2 in BMDMs ( Fig. 1d-f) . Additionally, ELISA demonstrated that these two drugs abolished TNF-α induced releases of IL-1β and IL-6 in a dose-dependent manner ( Fig. 1g-h ). Similar anti-TNF activity of Fexofenadine and Terfenadine was also observed in RAW264.7 cells (Fig. S5a-b ) and the BMDMs isolated from TNF-tg mice ( Fig. S6a-b) . TNF-α is known to enhance RANKL-stimulated osteoclastogenesis 25 . Both Fexofenadine and Terfenadine markedly inhibited TNF-α-mediated osteoclastogenesis in BMDMs (Fig. 1i) . In addition, dose-dependent inhibition of the TNF-tg/NF-κB pathway by Fexofenadine and Terfenadine in vivo was also revealed by use of TNF-tg/NF-κB-Luc reporter double mutant mice (Fig. 1j) .
Furthermore, the TNF-α-induced nuclear translocation and DNA binding activity of p65 were also inhibited by Fexofenadine and Terfenadine (Fig. 1k-m Terfenadine proven to be more effective than MTX, the current clinically-used small molecule drug for treating rheumatoid arthritis (Fig. 2b-c) . In order to observe the response of inflammatory arthritis progression to Fexofenadine and Terfenadine, we stopped treatment at the 17-week-time point and resumed treatment at 19-week-time point. Ceasing the treatment led to an abrupt increase of the arthritis clinical scores. Once the treatment resumed, there was an immediate reduction in swelling score, indicating that the inflammatory arthritis induced by TNF-α overexpression responds well to both Fexofenadine and Terfenadine ( Fig.   2b-c) . H&E staining of ankle and knee tissues confirmed the inhibition of inflammatory degeneration (Fig. 2d) . TRAP staining of paw and skull showed a preventative effect of treatment upon osteoclast differentiation (Fig. 2e) . In addition, the drugs reduced cartilage loss, as revealed by Safranin O staining of ankle and knee (Fig. 2f) . We also measured the serum levels of IL-1β and IL-6 and found that the levels of these inflammatory cytokines were significantly reduced in Fexofenadine-and Terfenadine-treated groups compared to the control group (Fig. 2g-h ).
To determine drug's therapeutic effects, we started treatment when the TNF-tg mice with the swelling score of approximately 8 points. Both Fexofenadine and Terfenadine showed effective therapeutic effects in a dose-dependent manner ( Fig. 2i-j) . Taken Fig. 3a-b) . Analogously, Fexofenadine and Terfenadine could not only delay the onset of disease, but also significantly decrease arthritis clinical scores and incidence ( Fig.   3c-d) . Histological analysis showed less inflammation in treatment groups as compared to control group (Fig. 3e) . Fewer osteoclasts and less bone destruction were detected in the treated groups, as revealed by TRAP staining and microCT images (Fig. 3f-g ). Additionally, Fexofenadine and Terfenadine also prevented the loss of cartilage (Fig. 3h) , and significantly reduced the serum levels of IL-1β and IL-6 ( Fig. 3i-j) .
To determine drug's therapeutic effects, we started treatment when the CIA model mice displayed a clinical score of approximately 5 points of a maximum 16 points per animal 28 .
Both Fexofenadine and Terfenadine dose-dependently ameliorated disease scores ( Fig. 3k-l) .
Meanwhile, the serum levels of inflammatory cytokines IL-1β and IL-6 were significantly decreased in the treatment groups versus vehicle ( Fig. 3m-p) . Collectively, these data indicate that Fexofenadine and Terfenadine have both preventive and therapeutic effects in CIA, an industrially used preclinical animal model for testing anti-RA drugs.
Fexofenadine and Terfenadine are therapeutic against inflammatory bowel diseases
To determine the therapeutic effects of Fexofenadine and Terfenadine in additional autoimmune diseases other than inflammatory arthritis, we established two inflammatory bowel disease models in 8-week old C57BL/6 mice: Dextran sulfate sodium (DSS)-and 2, 4, 6-trinitrobenzene sulfonic acid (TNBS)-induced experimental colitis models 29 . First, Fexofenadine, Terfenadine, or 5-aminosalicylic acid (5-ASA, serving as a positive control) was orally delivered 3 days before model induction for a total of 11 days. Fexofenadine and
Terfenadine dose-dependently prevented bleeding ( Fig. 4a and e) , body weight loss ( Fig. 4b and f), abnormal stool ( Fig. 4c and g ) and reduced colon shortening ( Fig. 4d and h ). In particular, high dosages of Fexofenadine completely prevented bleeding, and was more effective than the positive control 5-ASA (Fig. 4a) . Furthermore, the serum levels of IL-1β
and IL-6 were reduced in treatment groups compared to the vehicle group ( Fig. 4i-l 
cPLA2 is a novel target of Fexofenadine and Terfenadine
The anti-histaminic activity of Fexofenadine and Terfenadine are known to be mediated by targeting to their selective histamine H1 receptor 1 (H1R1) [30] [31] [32] . We next sought to determine whether the anti-TNF activity of Fexofenadine and Terfenadine depends on their known target H1R1. We thus suppressed the expression of H1R1 using its specific siRNAs in RAW264.7 cells, and found, unexpectedly, that suppression of H1R1 did not affect the inhibition of Fexofenadine and Terfenadine on TNF-induced cytokine release ( Fig. S10a-c ).
In addition, other 7 known H1R1 antagonists did not exhibit the anti-TNF activity and some of them even increased TNF-induced IL-6 release ( (Fig. S12a-c) . These findings led us to propose that Fexofenadine and
Terfenadine may have an additional new target that mediates their anti-TNF activity through a previously-unrecognized mechanism. To address this issue, we devoted significant effort to isolating protein binding partners of Fexofenadine and Terfenadine. After failure with several approaches, including labeling and biochemical co-purification, implementation of drug affinity responsive target stability (DARTS) assay 33 proven successful. We first mixed cell lysate with Fexofenadine or Terfenadine for 1h and protease was added for 15 min. The digested proteins were separated by SDS-PAGE, followed by Silver staining (Fig. 5a) , and a band with the molecular weight of approximately 80 kDa was found to be protected by Fexofenadine and Terfenadine. This band was excised from an accompanying Coomassie
Blue stained gel for protein identification by mass spectrometry (Fig. 5b) , which led to the identification of PLA2G4A encoding cPLA2 (Fig. 5c) and IKBKB encoding IKK-β as potential candidates. Both cPLA2 and IKK-β have appropriate molecular weights and are known to be the critical mediators of inflammation 23, 34 . To determine whether both cPLA2
and IKK-β are the targets of Fexofenadine and Terfenadine, we performed Western blot of DARTS samples with which a series of protease to cell lysate ratios were implemented ( (Fig. 5e, bottom) .
Performance of CETSA at 49ºC with different dosages of drugs revealed that Fexofenadine and Terfenadine prevented cPLA2 denaturation in a dose-dependent manner, with the EC50 of 1.025e-007 and 1.449e-009, respectively (Fig. 5f ).
To further characterize the interactions between Fexofenadine/Terfenadine and cPLA2, we performed both induced-fit docking (IFD) and molecular dynamics (MD) simulations. From IFD simulation, both Fexofenadine and Terfenadine core structures were predicted to stabilize at the MAPK phosphorylation site of cPLA2 at Ser-505 (Fig. 5g) . Docked poses of Fexofenadine in cPLA2 reveal that the Fexofenadine-binding region was lined by Ser-505
and several residues closed to Ser-505 (Fig. 5h) . Fexofenadine was predicted to be involved in two hydrogen bonding interactions with Ser-505. The predicted binding-region and hydrogen bonding interaction for Terfenadine were nearly the same as Fexofenadine (Fig. 5i) .
MD simulations, as a complement to IFD simulation, showed that Fexofenadine core cPLA2 contains several domains critical for its functions 37 , including Ca 2+ binding domain (C2D), catalytic domain 1 (CD1) and catalytic domain 2 (CD2) (Fig. 5j) . We sought to identify the domain by which Fexofenadine/Terfenadine targets to cPLA2. For this purpose,
we generated serial N-terminal and C-terminal deletion mutants and tested their interactions with Fexofenadine by use of DARTS (Fig. 5j) (Fig. 5k) , further demonstrating that Ser-505 is the critical amino acid required for Fexofenadine targeting to cPLA2.
It is well established that the phosphorylation of cPLA2 on Ser-505 by upstream kinases p-p38 and p-REK1/2 is required for its enzymatic activity 38 . Since Ser-505 is an essential amino acid of the binding site for Fexofenadine targeting to cPLA2, we next examined whether Fexofenadine affected TNF-activated phosphorylation of cPLA2 on Ser-505 (Fig.   6a ). As expected, TNF-α activated the phosphorylation of p38 and ERK1/2 as well as cPLA2
in BMDMs. Fexofenadine treatment did not affect the phosphorylation of p38 or ERK1/2, but abolished the phosphorylation of cPLA2 on Ser-505 (Fig. 6a) , further indicating that
Fexofenadine directly targets to cPLA2, without affecting its upstream mediators in the TNF-activated cPLA2 inflammatory pathway.
As mentioned earlier, the phosphorylation of cPLA2 on Ser-505 is required for its enzymatic activity, we next examined whether Fexofenadine/Terfenadine affected the activity of cPLA2.
Similar to arachidonyl trifluoromethyl ketone 27 (ATK), a known cPLA2 inhibitor and serving as a positive control, both Fexofenadine and Terfenadine completely abolished TNF-α induced cPLA2 activity and their inhibitions on cPLA2 activity are dosage-dependant (Fig. 6b) .
Inflammatory conditions, including elevated TNF-α, promote the cPLA2 translocation to intracellular phospholipid membrane. The major function of cPLA2 is to promote phospholipid hydrolysis to produce arachidonic acid (AA) 39 , which, in turn, actives NF-κB-mediated inflammation 23 . Consequently, we ascertained whether Fexofenadine and
Terfenadine inhibited TNF-α induced AA production, the data in We next sought to further determine the importance of cPLA2 in mediating Fexofenadine and
Terfenadine's anti-TNF-α activity. We deleted this gene using CRISPR-Cas9 technique (Fig.   6f ). This technology produced near complete deletion of cPLA2 (Fig. 6f) . Importantly, Fexofenadine and Terfenadine mediated inhibition of TNF-α activity was entirely or almost entirely lost in cPLA2 knockout cells, respectively (Fig. 6g-h ). Taken together, these findings indicated that cPLA2 is required for Fexofenadine and Terfenadine mediated anti-TNF-α activity.
DISCUSSION
TNF-α signaling associates with various pathophysiological processes and enormous efforts
have been devoted to develop treatments for TNF-α associated diseases and conditions 7, 9 . In this study we performed three rounds of screenings of an FDA-approved drug library, and Due to this alternate mechanism of action, Fexofenadine may be effective for up to ~50% of patients who fail to respond to current TNF-α blockers 12 . As a well-tolerated and generically available oral OTC drug, Fexomenadine's safety, convenience, and cost-effectiveness suggest that it may be an attractive and viable agent for the clinical treatment of inflammatory autoimmune diseases, particularly rheumatoid arthritis and inflammatory bowel diseases in which Fexofenadine has been proven to be effective in the preclinical animal models (Figs.
2-4, S7-9).
Fexofenadine is known to be a highly selective antagonist to H1 receptor 1 30, 42 . Surprisingly, suppression of H1 receptor 1 does not affect Fexofenadine-mediated anti-TNF-α activity (Fig.   S10 ). In addition, additional 7 known H1R1 inhibitors do not have anti-TNF activity (Fig.   S11 ). Although Fexofenadine potently inhibits TNF-α signaling in vitro and in vivo, it does not affect the binding of TNF-α to its receptors and cell surface, clearly different from clinically used TNF-α inhibitors (Fig. S12) . Excitingly, through combined use of drug affinity responsive target stability assay, proteomics, cellular thermal shift assay, induced-fit docking and molecular dynamics, we identified cPLA2 as a previously unrecognized target of . We found that both Fexofenadine and Terfenadine dose-dependently inhibited the expressions of inflammatory M1 macrophage-associated genes Il6 and Nos2 (Fig. S14a) , while markedly increased the expressions of anti-inflammatory M2 macrophage-associated genes Arg1 and Mgl1 (Fig. S14b) . Furthermore, Fexofenadine and Terfenadine significantly suppressed the differentiation of IFN -positive Th1 subpopulation. Fexofenadine also significantly inhibited Th17 cell differentiation, whereas negligible effects were observed with regard to the differentiation of Th2 and regulatory T cells (Tregs) (Fig. S15a-d) . It is expected that
Fexofenadine regulation of macrophages and T cells may also contribute to its anti-TNF/cPLA2 activity in vivo, which warrant further investigations. Additionally, although
Fexofenadine is therapeutic against inflammatory arthritis spontaneously developed in TNF-tg mice (Fig. 2) , and Fexofenadine-mediated anti-TNF-α activity depends on cPLA2
( Fig. 6f-h ), but not histamine H1 receptor (Fig. S10) , its anti-histaminic action may also contribute to its therapeutic effects in autoimmune diseases.
Similar to TNF-α, cPLA2 is also known to play an important role in regulating autoimmune diseases 43, 44 . cPLA2 is implicated in synovitis and joint destruction in rheumatoid arthritis by regulating the production of inflammatory mediators 45 . cPLA2 up-regulation leads to a greater disease severity phenotype in the DSS-induced colitis mouse model, whereas intravenous administration of antisense oligonucleotides against cPLA2 prevents disease development, suppresses NF-κB activation, and decreases expressions of pro-inflammatory proteins 46 , indicating the potential treatment target role of cPLA2 in colitis. Interestingly, Fexofenadine was reported to have potential treatment effects in the murine DSS-induced inflammatory bowel disease model through an unclear mechanism 47 . Our data demonstrating that Fexofenadine directly targets to cPLA2/AA and is therapeutic against inflammatory bowel disease link these previous reports together nicely and provide a mechanistic foundation for previous findings and future work.
In addition to autoimmune diseases, cPLA2 is also involved in the pathogenesis of many other disorders, particularly neurodegenerative diseases, cardiovascular diseases and cancer [48] [49] [50] [51] [52] [53] [54] [55] . Intense efforts have been invested to identify potent cPLA2α inhibitors in the past several decades, unfortunately, toxicity and the poor absorption of anti-cPLA2 compounds from intestine were the significant challenges for clinical application, although numerous cPLA2 inhibitors have been tested in clinical trials 56, 57 . Our findings that Fexofenadine, an OTC drug widely used for treating allergic diseases, targets and inhibits cPLA2 and is effective in various animal models of autoimmune diseases may provide innovative interventions to overcome the current bottlenecks in the efforts to develop cPLA2 targeting treatments.
In summary, this study identifies Fexofenadine as an inhibitor of TNFα signaling, and uncovers a new strategy for inhibiting this cardinal pathway of inflammation. In addition, this study also identifies cPLA2 as a new target of Fexofenadine, thus providing new insights into the understanding of Fexofenadine's action and underlying mechanisms, and a solid foundation for future discoveries relating to this Fexofenadine/cPLA2 interaction. Further, it also identifies Fexofenadine as a novel antagonist of cPLA2, suggesting that Fexofenadine can also be used for treating various cPLA2 associated diseases, including autoimmune diseases, neurodegenerative diseases, cardiovascular diseases and cancer. With the consideration that both TNF-α and cPLA2 are involved in a plethora of disease processes, the identification of Fexofenadine as an inhibitor of both TNF-α and cPLA2, and manipulation of new antagonist of the TNF/cPLA2 pathway may lead to innovative therapeutics for various pathologies and conditions, significantly broadening the application of this OTC drug in addition to allergic diseases.
METHODS SUMMARY
In vitro and in vivo screen of FDA-approved drug library: NF-κB-bla THP-1 cell line in which NF-κB beta-lactamase reporter gene was stably integrated, RAW 264.7 macrophages in which NF-κB luciferase reporter gene was transiently transfected, and TNF-tg:NF-κB-Luc double mutant reporter mice were employed to screen the drug library. 
In vitro and in vivo
